View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …

View Post

ONC201 Trial Begins for Endometrial and Breast Cancer

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for patients with certain types of advanced endometrial and breast cancer. The Phase II trial is led by Alexandra Zimmer, MD, Assistant Research Physician at the Women’s Malignancies Branch at the National Cancer Institute (NCI) Center for Cancer Research, part of the National …